Cardinal Health, Inc. (CAH) Cash Flow Statement

This extreme volatility suggests that Cardinal Health's cash conversion is dominated by massive, non-operational swings in working capital rather than the underlying profitability of its distribution business. The gap between net income and operating cash flow is not a signal of earnings quality but rather a reflection of the company's role as a financial intermediary, where timing of payments to suppliers and collections from customers creates enormous quarterly cash flow noise.

The FCF trajectory is almost entirely a function of working capital movements, not sustainable operational cash generation. For instance, the $2.8 billion FCF in 2025Q3 was driven by a $2.2 billion working capital release, which appears to be a timing benefit rather than a structural improvement. This pattern implies that investors should focus on gross profit and operating income trends, as FCF is too volatile to serve as a meaningful valuation metric for this business.

This pattern is consistent with a high-volume, low-margin distributor that must finance massive inventory levels and extend credit to large hospital and pharmacy customers. The magnitude of these swings suggests that Cardinal Health's cash flow is more reflective of its treasury management and payment terms than its core operational efficiency. Investors should monitor days sales outstanding and inventory turnover as leading indicators of future cash flow volatility.

The consistent dividend payments and aggressive buybacks suggest management is confident in the stability of the core pharmaceutical distribution cash flows, despite the volatility in reported FCF. However, the large acquisition in 2025Q3 ($2.8 billion) and subsequent smaller deals indicate a continued appetite for M&A, which could introduce integration risk and divert cash from debt reduction or further shareholder returns.